AI-Assisted Planning for Refractive Laser Eye Surgery
RLES AI reads your diagnostic printouts, screens dozens of risk parameters, applies your devices' own nomograms and delivers a signature-ready surgical plan — in minutes, over a simple WhatsApp message.
As easy as a WhatsApp message. No forms, no software, no learning curve — between consultations or on your way out of the OR, RLES AI is with you.
Send photos or PDFs of the patient's topography, pachymetry, autorefraction and exam notes.
Every value is read with its source, assigned to the correct eye, and run through the full safety engine.
A branded, signature-ready PDF planning report is produced and delivered on the same line.
Fourteen integrated modules cover the full journey of the refractive patient — from first screening to lifelong follow-up. Every recommendation is explainable, literature-backed, and always leaves the final decision with the surgeon.
Pre-operative planning for SMILE · LASIK · iLASIK · Q-LASIK · PRK · T-PRK. All six procedures are tested against their own procedure-specific safety floors, your devices' nomograms are applied, and a signature-ready planning report is produced.
Advanced multi-index analysis — BAD-D, ART, Kmax, ISK, IVA, CBI/TBI, posterior elevation — with a decision matrix and correlation-aware counting that never treats derived indices as independent evidence.
Finds deformed corneas that device software labels “Normal”. Nine indicators are screened together; oedema-inflated pachymetry — which silently flatters PTA, RSB and RCT all at once — is caught before it can mislead a plan.
Plans by the source of astigmatism, not just the manifest cylinder. Alpins double-angle analysis separates corneal and lenticular components; when the mismatch (ORA) is significant, a 60/40 vector-planning target protects the patient's long-term outcome.
A prevention engine that detects the preconditions of free flap, buttonhole and ectasia at the planning stage — plus a confidential in-clinic analysis module that investigates adverse events with mimic tables, severity grading and root-cause analysis.
Tissue has already been spent and the cornea carries a previous lamellar plane. RLES AI checks refractive stability, calculates the cumulative tissue budget and recommends the safest route for each eye.
When an eye is not suitable for laser, RLES AI shows the next best option — automatically. Indication ranges, age, endothelium and the notorious ACD measurement trap are all verified.
After detection comes the pathway: progression is assessed by consensus criteria, the CXL protocol is chosen by corneal thickness, and ring options are planned with brand-specific nomograms and femtosecond tunnel capability checks.
Detect. Classify. Optimize. Full two-arm DEWS II diagnosis with subtype and severity — plus an automatic tear-film signature screen that runs silently on every single topography you send.
AI-assisted candidate screening, personalized targets and expectation management for every presbyopic strategy — each plan run through the same tissue safety engine.
A one-page, bilingual, signed document the patient keeps for life — and history-based IOL support at cataract age. Standard formulas are not used on post-refractive eyes; hyperopic surprise is prevented with the right inputs.
Post-op results are recorded with a short message; efficacy, safety and predictability indices accumulate into your personal nomogram — and an adjustment is proposed only when your own statistics can defend it.
Once your decision is final, RLES AI writes a plain-language summary for the patient: why the treatment was found suitable, what the day looks like, the rules to follow and the follow-up calendar — reviewed and handed over by you.
RLES AI does not just answer; it explains the rule, the formula and the literature behind every recommendation. Which index is borderline and why. Why the hinge goes in that direction. Why the optical zone takes that value.
Every plan — no exceptions — passes through binding safety floors before it reaches your signature. Designed to catch the one case before it ever reaches the operating room.
AUTOMATICALLY TESTED. SAFETY VERIFIED. CONFIDENCE DELIVERED.
Register your clinic's devices once. From then on, every analysis applies the published nomograms and specifications of your platform — values are never substituted from another device.
THE RIGHT DEVICE. THE RIGHT SETTING. THE RIGHT OUTCOME.
RLES AI never rules that surgery “cannot be done”. It shows the floors, the reasons and the ways out — the decision always rests with the surgeon.
RLES AI® is a development and investment of MCD Technologies Investment Inc. — built rule by rule with founding refractive surgeons, verified against published device nomograms and current literature, and delivered as clinical decision support: for professional use, with the final clinical decision always resting with the surgeon.
Full platform launch: November 2026 — this page is an introduction while we complete onboarding for early-access clinics.
Tell us who you are and we will get back to you with details, demo access and early-adopter conditions.